Back to TLA

Barettin Analogs

Case ID:

UA25-223

Invention:

This invention features a novel barettin analogs, which are designed for the treatment of tuberculosis (TB) and chronic pain. Barettin, a naturally derived marine compound, has shown promising biological activity, and these synthetic analogs are optimized to enhance therapeutic effects while minimizing potential side effects. The innovation aims to offer a new avenue of treatment for two major health concerns with significant unmet medical needs. The analogs are structured to maximize efficacy and selectivity, with the potential to outperform traditional therapeutics. Their ability to treat tuberculosis—especially in an era of rising antibiotic resistance—and to provide non-opioid pain relief highlights their dual utility. This makes them valuable candidates for pharmaceutical development, particularly in areas where current treatment options are insufficient or carry high risk of dependency.

Background:
Tuberculosis remains a global health crisis, with over 10 million new cases and 1.3 million deaths annually. Current treatments are lengthy, involve multiple antibiotics, and are increasingly undermined by drug-resistant TB strains. Similarly, pain management heavily relies on opioids, which carry serious risks including addiction, tolerance, and overdose. There is a pressing need for new TB drugs that can address resistant strains and shorten treatment durations, as well as for non-opioid analgesics that provide effective relief without the dangers of dependence. Barettin analogs offer a promising alternative by leveraging unique biological mechanisms that differ from those of conventional therapies.

Applications: